A phase II, multicenter context of vulnerability study to determine the activity of brostallicin in the treatment of patients with one of the following cancers; 1) ovarian or breast with BRCA mutation, 2) hereditary nonpolyposis colorectal with mismatch repair deficiency and microsatellite instability.
Details to be posted soon.
What is Brostallicin? Brostallicin (bräst-al-iss-in) is a new class of cancer drug—a synthetic DNA minor groove binding agent. We are developing brostallicin for the treatment of advanced or metastatic soft tissue sarcoma. Learn more about brostallicin